Anti-CD4 monoclonal antibody [FITC] (CABT-45167MR)

Mouse Anti-Rabbit CD4 monoclonal antibody for FC

Additional Formats Available


Host Species
Antibody Isotype
Species Reactivity
Rabbit thymocytes


Application Notes
Flow Cyt: Neat
*Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own experiment using appropriate negative and positive controls.


Alternative Names
CD4; T-cell surface glycoprotein CD4; cell surface glycoprotein CD4; T-cell surface antigen T4/Leu-3
Entrez Gene ID
UniProt ID

Product Background

Antigen processing and presentation; Cell adhesion molecules (CAMs); Hematopoietic cell lineage; Primary immunodeficiency; T cell receptor signaling pathway;


Have you cited CABT-45167MR in a publication? Let us know and earn a reward for your research.

Customer Reviews

Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Mouse IgG2a Isotype Control [FITC] DAGIC1526 FC Mouse PDF Inquiry


Elevated expression of FREM1 in breast cancer indicates favorable prognosis and high-level immune infiltration status


Authors: Li, Han-ning; Li, Xing-rui; Lv, Zheng-tao; Cai, Miao-miao; Wang, Ge; Yang, Zhi-fang

Breast cancer (BC) poses one of the major threats to female's health worldwide. Immune infiltration in BC is a key representative of the tumor microenvironment and has been proven highly relevant for prognosis. The role of the FREM1 (FRAS1-Related Extracellular Matrix 1) gene in carcinoma has not studied, moreover, the underlying mechanism remains largely unknown. This study aims to investigate the expression profile and potential action of FREM1 on BC progression. We applied series of bioinformatic methods as well as immunohistochemistry (IHC) and immunofluorescence (IF) to analyze FREM1 expression profile, its relationship with clinicopathological characteristics, impact on clinical outcomes, relevant functions, correlation with immune infiltration in BC. The results demonstrated that FREM1 had a dramatically reduced expression in BC tissues, possessed an inverse correlation with stage, age, and metastasis, and exhibited a higher level in invasive lobular breast carcinoma than in ductal one. Furthermore, decreased FREM1 expression was often associated with estrogen receptor (ER)/progesterone receptor (PR) negative and triple negative breast carcinoma (TNBC) status while human epidermal growth factor 2 (Her-2) positive status, and considerably correlated with a worse overall survival (OS) and recurrence-free survival (RFS). Meanwhile, the univariate/multivariate Cox model revealed that low-FREM1 expression can be an independent prognostic factor for BC. Additionally, FREM1 was mainly involved in the cell metabolism and immune cells infiltration. Moreover, IHC and IF demonstrated a positive correlation of its expression with the immune infiltrating levels of CD4(+), CD8(+)T cells, and CD86(+)M1 macrophages while a negative correlation with CD68(+)pan-macrophages and CD163(+)M2 macrophages. These findings suggest that FREM1 can be a potential biomarker for evaluating the immune infiltrating status, and the BC prognosis.

IL-12-Induced Immune Suppressive Deficit During CD8+T-Cell Differentiation


Authors: Renavikar, Pranav S.; Sinha, Sushmita; Brate, Ashley A.; Borcherding, Nicholas; Crawford, Michael P.; Steward-Tharp, Scott M.; Karandikar, Nitin J.

Autoimmune diseases are characterized by regulatory deficit in both the CD4+ and CD8+ T-cell compartments. We have shown that CD8+ T-cells associated with acute relapse of multiple sclerosis are significantly deficient in their immune suppressive ability. We hypothesized that distinct CD8+ cytotoxic T-cell (Tc) lineages, determined by cytokine milieu during naive T-cell differentiation, may harbor differential ability to suppress effector CD4+ T-cells. We differentiated purified human naive CD8+ T-cells in vitro toward Tc0 (media control), Tc1 and Tc17 lineages. Using in vitro flow cytometric suppression assays, we observed that Tc0 and Tc17 cells had similar suppressive ability. In contrast, Tc1 cells showed significant loss of suppressive ability against ex vivo CD4+ T-cells and in vitro-differentiated Th0, Th1 and Th17 cells. Of note, Tc1 cells were also suboptimal in suppressing CD4-induced acute xenogeneic graft versus host disease (xGVHD) in vivo. Tc subtypes derived under various cytokine combinations revealed that IL-12-containing conditions resulted in less suppressive cells exhibiting dysregulated cytotoxic degranulation. RNA sequencing transcriptome analyses indicated differential regulation of inflammatory genes and enrichment in GM-CSF-associated pathways. These studies provide insights into the role of T-cell differentiation in CD8 suppressive biology and may reveal therapeutically targetable pathways to reverse suppressive deficit during immune-mediated disease.

Online Inquiry

Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:

Related Products

Related Resources

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

Inquiry Basket